[BPMX] BioPharmX Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 0.39 Change: -0.01 (-1.79%)
Ext. hours: 0.41 Change: 0.02 (4.51%)

chart BPMX

Refresh chart

Strongest Trends Summary For BPMX

BPMX is in the medium-term down -57% in 3 months and down -55% in 5 months and up 560% in 1 year. In the long-term up 995% in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.47 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-1
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-261.1% ROE-481.02% ROI
Current Ratio1.84 Quick Ratio Long Term Debt/Equity Debt Ratio0.84
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities8.37 M Cash From Investing Activities-260 K Cash From Operating Activities-6 M Gross Profit
Net Profit-2.78 M Operating Profit-2.78 M Total Assets2.99 M Total Current Assets2.52 M
Total Current Liabilities1.37 M Total Debt Total Liabilities1.37 M Total Revenue
Technical Data
High 52 week3.6 Low 52 week0.12 Last close1.35 Last change-1.46%
RSI29.76 Average true range1.73 Beta-0.39 Volume1.41 M
Simple moving average 20 days-32.34% Simple moving average 50 days-42.48% Simple moving average 200 days8.78%
Performance Data
Performance Week-20.59% Performance Month-39.12% Performance Quart-50.91% Performance Half680.8%
Performance Year542.55% Performance Year-to-date-49.95% Volatility daily8.81% Volatility weekly19.69%
Volatility monthly40.35% Volatility yearly139.78% Relative Volume67.32% Average Volume9.67 M
New High New Low

News

2019-06-11 16:10:00 | BioPharmX Reports Fiscal First Quarter 2020 Financial Results

2019-05-22 08:10:00 | BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular Rosacea

2019-04-26 07:30:00 | BioPharmX Completes 1-for-25 Reverse Stock Split

2019-04-15 16:15:00 | BioPharmX Announces Reverse Stock Split

2019-03-21 08:55:00 | BioPharmX Announces $3.9 Million Offering

2019-03-19 14:30:00 | Watch These Four Healthcare Stocks Set The Pace On Tuesday

2019-03-18 06:45:00 | BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare Conference

2019-03-14 16:05:00 | BioPharmX Reports Fourth Quarter and Full Year 2019 Financial Results

2019-03-13 09:30:30 | Can We See Significant Institutional Ownership On The BioPharmX Corporation NYSEMKT:BPMX Share Register?

2019-03-04 06:00:00 | BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea

2019-02-28 13:45:00 | These Four Tech Stocks Could Test February Highs

2019-02-27 16:15:00 | BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American

2019-02-04 07:00:00 | BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd Plott

2019-01-29 08:10:00 | Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX — Future Expectations, Projections Moving into 2019

2019-01-09 07:00:00 | Market Rally Extends to Biotech

2018-12-20 16:30:00 | BioPharmX Receives Notice of Noncompliance from NYSE American

2018-12-06 16:10:00 | BioPharmX Reports Third Quarter 2019 Financial Results

2018-12-05 06:19:26 | Is BioPharmX Corporation’s NYSEMKT:BPMX Balance Sheet Strong Enough To Weather A Storm?

2018-11-16 06:00:00 | BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing Compliance

2018-10-23 07:55:00 | Report: Exploring Fundamental Drivers Behind Helen of Troy, BioPharmX, Fair Isaac, Frontier Communications, ICU Medical, and Darling Ingredients — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-11 16:30:00 | BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea

2018-09-28 09:15:00 | BioPharmX Receives Notice of Noncompliance from NYSE American

2018-09-14 07:30:01 | Who Are The Major Shareholders In BioPharmX Corporation NYSEMKT:BPMX?

2018-09-12 17:30:00 | BioPharmX Corporation Announces David S. Tierney, M.D. Joined the Company as Chief Executive Officer

2018-09-12 08:00:00 | Today’s Research Reports on Stocks to Watch: Agile Therapeutics and BioPharmX

2018-08-30 16:15:00 | BioPharmX Reports Second Quarter 2019 Financial Results

2018-08-28 07:55:00 | Detailed Research: Economic Perspectives on Allegheny Technologies, Ring Energy, Aerohive Networks, Omeros, Adtalem Global Education, and BioPharmX — What Drives Growth in Today's Competitive Landscape

2018-08-14 18:00:00 | BioPharmX Announces Results of Annual Shareholders Meeting

2018-08-09 06:15:00 | BioPharmX Announces Patent Award, Expanding Protection for Innovations in Solid Dosage Forms

2018-07-31 09:15:00 | BioPharmX Receives IRB Approval to Initiate Phase 2 Trial of BPX-04 for the Treatment of Rosacea

2018-07-26 08:00:00 | Free Technical Insights on BioPharmX and Three Other Biotech Stocks

2018-07-20 09:25:45 | What Pushed BioPharmX Stock Up Yesterday?

2018-07-20 08:05:00 | Today’s Research Reports on Stocks to Watch: MiMedx Group and BiopharmX

2018-07-19 11:17:00 | 3 Biotech Stocks to Watch This Quarter

2018-07-19 09:15:00 | BioPharmX Announces FDA Grant of CARC Waiver and Post-Hoc Analysis for BPX-01

2018-06-27 08:15:00 | Report: Developing Opportunities within Valvoline, Parker Drilling, Dean Foods, BioPharmX, Hasbro, and Alnylam Pharmaceuticals — Future Expectations, Projections Moving into 2018

2018-06-19 09:15:00 | New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatology

2018-06-19 07:30:00 | Blog Exposure - bluebird bio Announces Encouraging New Data from Northstar HGB-204 and Northstar-2 HGB-207 Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent ?-Thalassemia

2018-06-19 07:00:00 | Free Technical Research on BioPharmX and Three More Biotech Equities bio

2018-06-07 16:15:00 | BioPharmX Reports First Quarter 2019 Financial Results

2018-06-07 10:30:00 | BioPharmX Displays Progress in BPX-01 and BPX-04 Clinicals, Pipeline Review and Target

2018-05-24 09:00:00 | BioPharmX Studies Show Hydrophilic Topical Minocycline Gels May Be the Preferred Treatment Option for Acne, Rosacea Patients

2018-05-15 12:11:10 | BioPharmX Corporation NYSEMKT:BPMX: What Does The Future Look Like?

2018-05-10 07:30:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Energy Transfer Equity, Mednax, BioPharmX, Owens & Minor, SunPower, and Convergys — New Research Emphasizes Economic Growth

2018-04-27 11:06:41 | Why BioPharmX Corporation’s NYSEMKT:BPMX Investor Composition Impacts Your Returns

2018-04-26 16:15:00 | BioPharmX Reports Fourth Quarter and Full Year 2018 Financial Results

2018-03-21 08:00:00 | Today’s Research Reports on Trending Tickers: BioPharmX and MediWound

2018-03-20 20:30:00 | BioPharmX Cancels Presentation at Oppenheimer's 28th Annual Healthcare Conference Due to Severe Weather

2018-03-20 09:15:00 | U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug Compositions

2018-03-14 09:15:00 | BioPharmX to Present at Oppenheimer's 28th Annual Healthcare Conference